Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 9/20 | 0.36 |
| ▸ | RCOR1 | Q9UKL0 | 9/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 7/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2811115 | 0.94 | MAPT (0.40) | SIGMAR1KDM1ARCOR1EHMT2MAPT | |
| SCHEMBL2810273 | 0.92 | ADORA3 (0.41) | SIGMAR1OGAMAPT | |
| SCHEMBL2813941 | 0.92 | ADORA3 (0.41) | SIGMAR1OGAMAPT | |
| SCHEMBL2812972 | 0.92 | SIGMAR1 (0.38) | MCHR1SIGMAR1MAPT | |
| SCHEMBL2812214 | 0.88 | ADORA2A (0.42) | SIGMAR1 | |
| SCHEMBL2813048 | 0.86 | IP6K1 (0.40) | SIGMAR1KDM1ARCOR1EHMT2 | |
| SCHEMBL2811035 | 0.86 | ACHE (0.37) | OGAMAPT | |
| SCHEMBL537584 | 0.86 | ACHE (0.45) | SIGMAR1EHMT2MAPT | |
| SCHEMBL2812918 | 0.85 | MRGPRX1 (0.38) | SIGMAR1MAPT | |
| SCHEMBL2810531 | 0.85 | MRGPRX1 (0.48) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | MCHR1 4806/4885SIGMAR1 4535/4885OGA 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.